Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations - PubMed (original) (raw)
Launching invasive, first-in-human trials against Parkinson's disease: ethical considerations
Jonathan Kimmelman et al. Mov Disord. 2009.
Abstract
The decision to initiate invasive, first-in-human trials involving Parkinson's disease presents a vexing ethical challenge. Such studies present significant surgical risks, and high degrees of uncertainty about intervention risks and biological effects. We argue that maintaining a favorable risk-benefit balance in such circumstances requires a higher than usual degree of confidence that protocols will lead to significant direct and/or social benefits. One critical way of promoting such confidence is through the application of stringent evidentiary standards for preclinical studies. We close with a series of recommendations for strengthening the internal and external validity of preclinical studies, reducing their tendency toward optimism and publication biases, and improving the knowledge base used to design and evaluate preclinical studies.
Similar articles
- Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson's disease.
Master Z, McLeod M, Mendez I. Master Z, et al. J Med Ethics. 2007 Mar;33(3):169-73. doi: 10.1136/jme.2005.013169. J Med Ethics. 2007. PMID: 17329391 Free PMC article. Review. - Ethical issues in naturalistic versus controlled trials.
Helmchen H. Helmchen H. Dialogues Clin Neurosci. 2011;13(2):173-82. doi: 10.31887/DCNS.2011.13.2/hhelmchen. Dialogues Clin Neurosci. 2011. PMID: 21842614 Free PMC article. - The ethics of sham surgery in Parkinson's disease: back to the future?
Swift T, Huxtable R. Swift T, et al. Bioethics. 2013 May;27(4):175-85. doi: 10.1111/j.1467-8519.2011.01931.x. Epub 2011 Dec 13. Bioethics. 2013. PMID: 22150772 Free PMC article. - Clinical/surgical considerations.
Foltynie T, Zrinzo L. Foltynie T, et al. Handb Clin Neurol. 2024;205:101-110. doi: 10.1016/B978-0-323-90120-8.00006-X. Handb Clin Neurol. 2024. PMID: 39341647 Review. - Ethical considerations for the conduct of antidementia trials in Canada.
Fisk JD. Fisk JD. Can J Neurol Sci. 2007 Mar;34 Suppl 1:S32-6. doi: 10.1017/s0317167100005539. Can J Neurol Sci. 2007. PMID: 17469679 Review.
Cited by
- Reframing the perception of outliers and negative data in translational research.
Emborg ME. Emborg ME. Brain Res Bull. 2023 Jan;192:203-207. doi: 10.1016/j.brainresbull.2022.11.020. Epub 2022 Dec 1. Brain Res Bull. 2023. PMID: 36464129 Free PMC article. Review. - A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys.
Ohshima-Hosoyama S, Simmons HA, Goecks N, Joers V, Swanson CR, Bondarenko V, Velotta R, Brunner K, Wood LD, Hruban RH, Emborg ME. Ohshima-Hosoyama S, et al. PLoS One. 2012;7(6):e39036. doi: 10.1371/journal.pone.0039036. Epub 2012 Jun 20. PLoS One. 2012. PMID: 22745701 Free PMC article. - Methodological standards, quality of reporting and regulatory compliance in animal research on amyotrophic lateral sclerosis: a systematic review.
Fernandes JG, Franco NH, Grierson AJ, Hultgren J, Furley AJW, Olsson IAS. Fernandes JG, et al. BMJ Open Sci. 2019 Aug 1;3(1):e000016. doi: 10.1136/bmjos-2018-000016. eCollection 2019. BMJ Open Sci. 2019. PMID: 35047680 Free PMC article. - Why primate models matter.
Phillips KA, Bales KL, Capitanio JP, Conley A, Czoty PW, 't Hart BA, Hopkins WD, Hu SL, Miller LA, Nader MA, Nathanielsz PW, Rogers J, Shively CA, Voytko ML. Phillips KA, et al. Am J Primatol. 2014 Sep;76(9):801-27. doi: 10.1002/ajp.22281. Epub 2014 Apr 10. Am J Primatol. 2014. PMID: 24723482 Free PMC article. Review. - Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.
Kimmelman J, London AJ. Kimmelman J, et al. PLoS Med. 2011 Mar;8(3):e1001010. doi: 10.1371/journal.pmed.1001010. Epub 2011 Mar 8. PLoS Med. 2011. PMID: 21423344 Free PMC article. No abstract available.
References
- Ravina B, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment. Neurology. 2003;60:1234–1240. - PubMed
- Nakamura K, Christine CW, Starr PA, Marks WJ., Jr Effects of unilateral subthalamic and pallidal deep brain stimulation on fine motor functions in Parkinson's disease. Mov Disord. 2007;22:619–626. - PubMed
- Dass B, Olanow W, Kordower JH. Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson’s disease. Neurology. 2006;66:S89–S103. - PubMed
- Freeman TB, Vawter DE, Leaverton PE, et al. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med. 1999;23:988–992. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical